Aurinia Pharmaceuticals (AUPH) Return on Sales (2019 - 2025)
Historic Return on Sales for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to 0.43%.
- Aurinia Pharmaceuticals' Return on Sales rose 2200.0% to 0.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year increase of 4000.0%. This contributed to the annual value of 0.02% for FY2024, which is 4700.0% up from last year.
- Per Aurinia Pharmaceuticals' latest filing, its Return on Sales stood at 0.43% for Q3 2025, which was up 2200.0% from 0.31% recorded in Q2 2025.
- Aurinia Pharmaceuticals' Return on Sales' 5-year high stood at 0.43% during Q3 2025, with a 5-year trough of 55.12% in Q1 2021.
- For the 5-year period, Aurinia Pharmaceuticals' Return on Sales averaged around 3.78%, with its median value being 0.28% (2023).
- Per our database at Business Quant, Aurinia Pharmaceuticals' Return on Sales surged by 14493300bps in 2021 and then tumbled by -900bps in 2023.
- Aurinia Pharmaceuticals' Return on Sales (Quarter) stood at 1.42% in 2021, then skyrocketed by 36bps to 0.92% in 2022, then surged by 35bps to 0.6% in 2023, then soared by 104bps to 0.02% in 2024, then soared by 1645bps to 0.43% in 2025.
- Its last three reported values are 0.43% in Q3 2025, 0.31% for Q2 2025, and 0.37% during Q1 2025.